SLC5A2 and type 2 diabetes mellitus: After analyzing the FDA Adverse Event Reporting System (FAERS) for incidences of acidosis in patients treated with SGLT2 inhibitors, Blau et al. found a sevenfold increase in developing acidosis in patients with type 2 diabetes on the drug.